LifeCell Strengthens its Position, Signs Pact to Service Cryo-Save India customers

IMT News Desk
IMT News Desk
· 3 min read
LifeCell logo

LifeCell, India’s first and largest umbilical cord stem cell bank has today announced signing of a formal agreement with Cryo-Save India (Cryo-Save) for formal transfer of all of its 18,000 cryo-preserved umbilical cord units and corresponding customer agreements to LifeCell.

There will be no change in the client agreement signed by customers with Cryo-Save India and LifeCell shall continue to service these customers

The cryopreserved stem cells currently under the care of Cryo-Save would be transported to LifeCell’s preservation facility at Chennai. This transportation would occur in phases and is expected to take up to 3 months for completion.

Further to the reassignment of the agreement to LifeCell, the customers of Cryo-Save will have opportunities to reap greater benefits of the decision to preserve their baby’s stem cells. Through LifeCell’s community stem cell banking program, these customers can now upgrade to receive unlimited access to a large, growing inventory of donor stem cells to get complete protection of stem cells for the entire family. Furthermore, by upgrading to the Lifetime Storage Plan, the stem cell samples can be preserved for the entire lifetime of the baby.

Speaking on the occasion Mayur Abhaya, MD, CEO, LifeCell said , “This transfer marks an important step to expand our business by leveraging our infrastructure and storage standards. It would also further strengthen our endeavor of becoming the country’s largest registry of cord blood stem cells. We are happy to welcome these 18,000 families into the ambit of our community and also extend benefits such as complete family protection and unlimited access to matching stem cells. We look forward to providing best-in-class service to the new members of the LifeCell family.”

LifeCell’s state-of-the-art storage facility in Chennai and Gurgaon currently houses more than 2,70,000 samples preserved umbilical cord blood and tissue stem cell units.

Roderick M Stuart, MD, Cryo-Save India said, “We are happy to enter into this transaction with LifeCell – India’s first and largest stem cell bank which provides highest quality services. LifeCell’s state-of-the-art facility, laboratory standards and excellent customer relations made a great match for us. We are happy that the families who had preserved with us would continue to be provided with same high-quality stem cell preservation service for years to come.”

Cryo-Save AG the brand and trademark owner has been storing umbilical cord stem cells for families all over the world since the year 2000. Cryo-Save India Pvt. Ltd. stored its first sample in India in the year 2008 at their processing and storage facility in Bangalore.

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk